Skip to content

Study on the combined effect of Lodhradi Vidalaka and Gandhaka Rasayana in Atopic Dermatitis affecting the eyelids

Combined effect of Lodhradi Vidalaka and Gandhaka Rasayana in Atopic Dermatitis affecting the eyelids-An Observational Clinical Study

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/05/052923
Enrollment
30
Registered
2023-05-19
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H011- Noninfectious dermatoses of eyelid

Interventions

None listed

Sponsors

DR P PREETHI
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Participants who are fulfilling the diagnostic criteria of atopic eyelid changes. 2.Participants of either gender above the age of 20 and below 60 years of age.

Exclusion criteria

Exclusion criteria: 1.Participants with other types of eyelid diseases like seborrheic dermatitis, contact dermatitis and squamous and ulcerative blepharitis. 2.Participants suffering from any other type of infectious and inflammatory eye conditions like stye, internal and external hordeolum, conjunctivitis, keratitis and uveitis. 3.Lacrimation of the eyes due to reflex lacrimation and epiphora. 4.Participants who are a known case of diabetes mellitus and hypertension. 5.Pregnant women.

Design outcomes

Primary

MeasureTime frame
Reduction in signs and symptoms of the diseaseTimepoint: Baseline data - Week 1,Week 3, and Week 6

Secondary

MeasureTime frame
Reduction in the following signs 1.Thickening 2.Crusting 3.Vertical fissuring 4.DrynessTimepoint: Baseline data day 0,5th day,15th day, and 45th day

Countries

India

Contacts

Public ContactDR P PREETHI

Sri Dharmasthala Manjunatheshwara College Of Ayurveda And Hospital Hassan

amarnath.hk@gmail.com9449324848

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026